Pacific Biosciences Announces Retirement of Michael Phillips, SVP of Research and Development
February 07 2020 - 4:03PM
Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading
provider of high-quality sequencing of genomes, transcriptomes and
epigenomes, today announced that Michael Phillips has decided to
retire from his role as the company’s Senior Vice President of
Research and Development as of April 1, 2020.
Mr. Phillips has directed the development of PacBio’s technology
since joining the company in 2005. During his tenure, he oversaw
the development of the company’s first system, the PacBio RS, which
was launched in 2011, and each of the company’s follow-on systems,
including the PacBio RS II in 2013, the Sequel System in 2015, and
most recently the Sequel II System in 2019.
“It has truly been an honor to lead Research and Development at
Pacific Biosciences for the last 15 years. I have had the privilege
of working with an exceptional team of scientists and engineers who
have taken our technologies from the lab and transformed them into
highly successful commercial products that are playing a principal
role in the emerging genomics revolution. Even though I am
concluding my career at PacBio, I look forward to following its
progress and continued success, as Denis and the Research and
Development team continue to push forward the technology’s
potential,” said Mr. Phillips.
“Michael has been a key contributor for PacBio since its early
days, and he has been at the helm of the company’s R&D efforts
throughout most of its history,” said Michael Hunkapiller, Chairman
and Chief Executive Officer of Pacific Biosciences. “PacBio
launched the first long-read sequencer in 2011 with its novel SMRT
technology and has leveraged the same technology to produce
sequencers today with up to 100,000 times the throughput of those
early systems. We are fortunate to have had Michael lead our
development efforts throughout this period. On behalf of myself and
the company, I extend our thanks to Michael for his many
contributions to PacBio.”
Denis Zaccarin, PhD will succeed Mr. Phillips as the company’s
head of research and development. Dr. Zaccarin joined PacBio in
2004 and has been an integral part of the company’s R&D team,
most recently serving as Vice President of Semiconductor Integrated
Devices, the team that is responsible for designing and developing
the company’s SMRT Cells.
“I am humbled and excited by this opportunity to lead PacBio’s
Research and Development team,” said Dr. Zaccarin. “Michael leaves
a strong legacy of outstanding leadership at PacBio that I am
committed to uphold. I believe the potential benefits of SMRT
sequencing are just beginning to be realized.”
About Pacific Biosciences Pacific Biosciences
of California, Inc. (NASDAQ:PACB) offers sequencing systems to help
scientists resolve genetically complex problems. Based on its novel
Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences’
products enable: de novo genome assembly to finish genomes in order
to more fully identify, annotate and decipher genomic structures;
full-length transcript analysis to improve annotations in reference
genomes, characterize alternatively spliced isoforms in important
gene families, and find novel genes; targeted sequencing to more
comprehensively characterize genetic variations; and real-time
kinetic information for epigenome characterization. Pacific
Biosciences’ technology provides high accuracy, ultra-long reads,
uniform coverage, and the ability to simultaneously detect
epigenetic changes. PacBio® sequencing systems, including
consumables and software, provide a simple, fast, end-to-end
workflow for SMRT Sequencing. More information is available at
www.pacb.com.
Forward-Looking Statements All statements in
this press release that are not historical are forward-looking
statements, including, among other things, statements relating to
future products, markets or market adoption, availability, uses,
accuracy, quality or performance of, or benefits of using, products
or technologies, the suitability or utility of products or
technologies for particular applications or projects, the expected
benefits of appointing Dr. Zaccarin as the head of research and
development and other future events. You should not place undue
reliance on forward-looking statements because they involve known
and unknown risks, uncertainties, changes in circumstances and
other factors that are, in some cases, beyond Pacific Biosciences’
control and could cause actual results to differ materially from
the information expressed or implied by forward-looking statements
made in this press release. Factors that could materially affect
actual results can be found in Pacific Biosciences’ most recent
filings with the Securities and Exchange Commission, including
Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and
10-Q, and include those listed under the caption “Risk
Factors.”
Pacific Biosciences undertakes no obligation to revise or update
information in this press release to reflect events or
circumstances in the future, even if new information becomes
available.
Contacts Media: Nicole Litchfield 415.793.6468
nicole@bioscribe.com
Investors: Trevin Rard 650.521.8450
ir@pacificbiosciences.com
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Sep 2023 to Sep 2024